Oscar Health, Inc. (OSCR)
| Market Cap | 8.51B +142.5% |
| Revenue (ttm) | 13.30B +31.9% |
| Net Income | -39.43M |
| EPS | -0.15 |
| Shares Out | 301.18M |
| PE Ratio | n/a |
| Forward PE | 25.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,046,267 |
| Open | 28.63 |
| Previous Close | 28.91 |
| Day's Range | 27.53 - 28.86 |
| 52-Week Range | 10.69 - 29.42 |
| Beta | 2.39 |
| Analysts | Hold |
| Price Target | 22.60 (-20.03%) |
| Earnings Date | May 6, 2026 |
About OSCR
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health prod... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for OSCR stock is "Hold." The 12-month stock price target is $22.6, which is a decrease of -20.03% from the latest price.
News
Nike downgraded, Oscar Health upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by…
Barclays upgrades Oscar Health on exposure to individual ACA market
Barclays analyst Andrew Mok upgraded Oscar Health (OSCR) to Overweight from Equal Weight with a price target of $35, up from $30. The firm says that with “single-line exposure” to…
Oscar Health upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Andrew Mok upgraded Oscar Health (OSCR) to Overweight from Equal Weight with a $35 price target
Oscar Health Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
2026 performance is strong, with favorable utilization and lighter-than-expected market morbidity. Product strategy and risk management are benefiting from conservative planning, while regulatory changes and market exits shape the outlook for 2027. AI-driven integrity measures support a stable marketplace.
Oscar Health Transcript: AGM 2026
The meeting covered board transitions, strong 2025 financial results with $11.7B revenue, and a near doubling of market share to 30%. All proposals, including director elections and auditor ratification, passed. No questions were submitted during the Q&A.
Oscar Health up 2% to $20.81 after Wells Fargo upgrade
05:29 EDT Oscar Health (OSCR) up 2% to $20.81 after Wells Fargo upgrade
Oscar Health upgraded to Equal Weight from Underweight at Wells Fargo
Wells Fargo analyst Stephen Baxter upgraded Oscar Health (OSCR) to Equal Weight from Underweight with a price target of $20, up from $11. The firm cites greater confidence in the…
Oscar Health price target raised to $30 from $21 at Barclays
Barclays raised the firm’s price target on Oscar Health (OSCR) to $30 from $21 and keeps an Equal Weight rating on the shares. The firm believes the managed care stock…
Oscar Health price target raised to $19 from $15 at Baird
Baird raised the firm’s price target on Oscar Health (OSCR) to $19 from $15 and keeps a Neutral rating on the shares. The firm updated its model following strong Q1…
Oscar Health price target raised to $20 from $15 at UBS
UBS analyst Jonathan Yong raised the firm’s price target on Oscar Health (OSCR) to $20 from $15 and keeps a Neutral rating on the shares.
Oscar Health price target raised to $21 from $18 at Barclays
Barclays raised the firm’s price target on Oscar Health (OSCR) to $21 from $18 and keeps an Equal Weight rating on the shares. The firm updated the company’s model post…
Oscar Health reports Q1 EPS $2.07, consensus $1.10
Reports Q1 revenue $4.65B, consensus $4.92B. “Oscar Health (OSCR) drove solid first-quarter performance with significant year-over-year improvements across our core metrics,” said Mark Bertolini, CEO....
Oscar Health Earnings Call Transcript: Q1 2026
First quarter 2026 saw record revenue and net income, with 56% membership growth and improved margins. Technology and AI drove operational efficiency, and guidance for the full year was reaffirmed amid favorable market trends.
Oscar Health Earnings release: Q1 2026
Oscar Health released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Oscar Health Quarterly report: Q1 2026
Oscar Health has published its Q1 2026 quarterly earnings report on May 6, 2026.
Oscar Health Reports Record Profit As Obamacare Enrollment Jumps
Health insurer Oscar Health swung to a $679 million first quarter profit – the highest in company history – as its health plan membership jumped more than 50% and medical costs eased.
Oscar Health Announces Strong Financial Results for First Quarter 2026 And Reaffirms 2026 Guidance
NEW YORK--(BUSINESS WIRE)--Oscar Health Announces Strong Financial Results for First Quarter 2026 And Reaffirms 2026 Guidance.
Oscar Health Proxy statement: Proxy filing
Oscar Health filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Oscar Health Proxy statement: Proxy filing
Oscar Health filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Oscar Health, Inc. Appoints Director Siddhartha Sankaran as Independent Chair of the Board
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. Appoints Director Siddhartha Sankaran as Independent Chair of the Board.
Meet Lucie. A New Way to Shop for Healthcare.
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (NYSE: OSCR) today launched Lucie Health Marketplace, a new all-in-one storefront that begins to change how America shops for healthcare. Lucie connects c...
Oscar Health, Inc. 2026 First Quarter Earnings Conference Call
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. 2026 First Quarter Earnings Conference Call.
Oscar Health Transcript: 47th Annual Raymond James Institutional Investor Conference
After a challenging 2025, proactive planning and strategic plan design led to strong 2026 enrollment and improved retention, with pricing and risk management reflecting lessons learned. Regulatory changes and integrity measures are expected to further stabilize the market.